Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia

Journal of Leukocyte Biology

Volumn 79, Issue 6, 2006, Pages 1157-1165

  Alfonso Pérez, Manuel ^a   López Giral, Sonia ^a   Quintana, Nuria E ^a   Loscertales, Javier ^a   Martín Jiménez, Patricia ^b   Muñoz, Cecilia ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Chemokines; Chemotaxis; Cytotoxicity; Immunotherapy; Metastasis; Tumor

Indexed keywords

ALEMTUZUMAB; CCR7 MAB ANTIBODY; CHEMOKINE RECEPTOR CCR7; MONOCLONAL ANTIBODY; RITUXIMAB; BETA CHEMOKINE; CC CHEMOKINE RECEPTOR 7; CHEMOKINE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; TUMOR ANTIGEN;

ARTICLE; CELL MIGRATION; CYTOTOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHADENOPATHY; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE SPECIFICITY; TUMOR CELL; AGED; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; APOPTOSIS; CELL DIVISION; CHRONIC LYMPHATIC LEUKEMIA; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENDOCYTOSIS; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MOUSE; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; SPECIES DIFFERENCE; TUMOR CELL LINE;

MURINAE;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCYTOSIS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MICE; MIDDLE AGED; RECEPTORS, CHEMOKINE; SPECIES SPECIFICITY; T-LYMPHOCYTES;

EID: 33746908207     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1105623     Document Type: Article

References (63)

1. Byrd, J. C., Peterson, B. L., Morrison, V. A., Park, K., Jacobson, R., Hoke, E., Vardiman, J. W., Rai, K., Schiffer, C. A., Larson, R. A. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101, 6-14.
2. Byrd, J. C., Rai, K., Peterson, B. L., Appelbaum, F. R., Morrison, V. A., Kolitz, J. E., Shepherd, L., Hines, J. D., Schiffer, C. A., Larson, R. A. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53.
3. Keating, M. J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M. A., Lynn, A., Kantarjian, H. (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088.
4. Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K. A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H., Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4070-4078.
5. Kay, N. E. (2006) Treatment and evaluation of CLL: a complicated affair. Blood 107, 848.
6. Countouriotis, A., Moore, T. B., Sakamoto, K. M. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20, 215-229.
7. Villamor, N., Montserrat, E., Colomer, D. (2003) Mechanism of action and resistance to monoclonal antibody therapy. Semin. Oncol. 30, 424-433.
8. Olszewski, A. J., Grossbard, M. L. (2004) Empowering targeted therapy: lessons from rituximab. Sci. STKE 2004, pe30.
9. Lopez-Giral, S., Quintana, N. E., Cabrerizo, M., Alfonso-Perez, M., Sala-Valdes, M., De Soria, V. G., Fernandez-Ranada, J. M., Fernandez-Ruiz, E., Munoz, C. (2004) Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J. Leukoc. Biol. 76, 462-471.
10. Till, K. J., Lin, K., Zuzel, M., Cawley, J. C. (2002) The chemokine receptor CCR7 and α4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 99, 2977-2984.
11. Hasegawa, H., Nomura, T., Kohno, M., Tateishi, N., Suzuki, Y., Maeda, N., Fujisawa, R., Yoshie, O., Fujita, S. (2000) Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 95, 30-38.
12. Hopken, U. E., Foss, H. D., Meyer, D., Hinz, M., Leder, K., Stein, H., Lipp, M. (2002) Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 99, 1109-1116.
13. Kallinich, T., Muche, J. M., Qin, S., Sterry, W., Audring, H., Kroczek, R. A. (2003) Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J. Invest. Dermatol. 121, 1045-1052.
14. Forster, R., Ohl, L., Henning, G. (2001) Lessons learned from lymphocytes: CC chemokine receptor-7 involved in lymphogenic metastasis of melanoma. J. Natl. Cancer Inst. 93, 1588-1589.
15. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegui, E., Zlotnik, A. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
16. Mashino, K., Sadanaga, N., Yamaguchi, H., Tanaka, F., Ohta, M., Shibuta, K., Inoue, H., Mori, M. (2002) Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62, 2937-2941.
17. Ding, Y., Shimada, Y., Maeda, M., Kawabe, A., Kaganoi, J., Komoto, I., Hashimoto, Y., Miyake, M., Hashida, H., Imamura, M. (2003) Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9, 3406-3412.
18. Takanami, I. (2003) Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int. J. Cancer 105, 186-189.
19. Wang, J., Xi, L., Hunt, J. L., Gooding, W., Whiteside, T. L., Chen, Z., Godfrey, T. E., Ferris, R. L. (2004) Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 64, 1861-1866.
20. Cyster, J. G. (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102.
21. Potsch, C., Vohringer, D., Pircher, H. (1999) Distinct migration patterns of naive and effector CD8 T cells in the spleen: correlation with CCR7 receptor expression and chemokine reactivity. Eur. J. Immunol. 29, 3562-3570.
22. Okada, T., Ngo, V. N., Ekland, E. H., Forster, R., Lipp, M., Littman, D. R., Cyster, J. G. (2002) Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J. Exp. Med. 196, 65-75.
23. Reif, K., Ekland, E. H., Ohl, L., Nakano, H., Lipp, M., Forster, R., Cyster, J. G. (2002) Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 416, 94-99.
24. Muller, G., Lipp, M. (2003) Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafficking. Microcirculation 10, 325-334.
25. Junt, T., Scandella, E., Forster, R., Krebs, P., Krautwald, S., Lipp, M., Hengartner, H., Ludewig, B. (2004) Impact of CCR7 on priming and distribution of antiviral effector and memory CTL. J. Immunol. 173, 6684-6693.
26. Yoshie, O., Imai, T., Nomiyama, H. (1997) Novel lymphocyte-specific CC chemokines and their receptors. J. Leukoc. Biol. 62, 634-644.
27. Dieu, M. C., Vanbervliet, B., Vicari, A., Bridon, J. M., Oldham, E., Ait-Yahia, S., Briere, F., Zlotnik, A., Lebecque, S., Caux, C. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188, 373-386.
28. Kim, C. H., Pelus, L. M., White, J. R., Applebaum, E., Johanson, K., Broxmeyer, H. E. (1998) CK β-11/macrophage inflammatory protein-3 β/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells. J. Immunol. 160, 2418-2424.
29. Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C. R., Qin, S., Lanzavecchia, A. (1998) Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28, 2760-2769.
30. Sozzani, S., Allavena, P., D'Amico, G., Luini, W., Bianchi, G., Kataura, M., Imai, T., Yoshie, O., Bonecchi, R., Mantovani, A. (1998) Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161, 1083-1086.
31. Willimann, K., Legler, D. F., Loetscher, M., Roos, R. S., Delgado, M. B., Clark-Lewis, I., Baggiolini, M., Moser, B. (1998) The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur. J. Immunol. 28, 2025-2034.
32. Yoshida, R., Nagira, M., Imai, T., Baba, M., Takagi, S., Tabira, Y., Akagi, J., Nomiyama, H., Yoshie, O. (1998) EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly upregulate CCR7 and efficiently migrate toward ELC. Int. Immunol. 10, 901-910.
33. van Dongen, J. J., Langerak, A. W., Bruggemann, M., Evans, P. A., Hummel, M., Lavender, F. L., Delabesse, E., Davi, F., Schuuring, E., Garcia-Sanz, R., van Krieken, J. H., Droese, J., Gonzalez, D., Bastard, C., White, H. E., Spaargaren, M., Gonzalez, M., Parreira, A., Smith, J. L., Morgan, G. J., Kneba, M., Macintyre, E. A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17, 2257-2317.
34. Gonzalez, M., Gonzalez, D., Lopez-Perez, R., Garcia-Sanz, R., Chillon, M. C., Balanzategui, A., Mateos, M. V., Alaejos, I., Langerak, A. W., Orfao, A., Van Dongen, J. J., San Miguel, J. F. (1999) Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies. Haematologica 84, 779-784.
35. Cook, G. P., Tomlinson, I. M. (1995) The human immunoglobulin VH repertoire. Immunol. Today 16, 237-242.
36. Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A., Mackay, C. R. (1997) The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94, 1925-1930.
37. Tarasova, N. I., Stauber, R. H., Michejda, C. J. (1998) Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4. J. Biol. Chem. 273, 15883-15886.
38. Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J. P., Jacob, M. C., Sotto, J. J., Leroux, D., Bensa, J. C., Plumas, J. (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101, 949-954.
39. Pangalis, G. A., Dimopoulou, M. N., Angelopoulou, M. K., Tsekouras, C., Vassilakopoulos, T. P., Vaiopoulos, G., Siakantaris, M. P. (2001) Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med. Oncol. 18, 99-107.
40. Huhn, D., von Schilling, C., Wilhelm, M., Ho, A. D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Serke, S., Peschel, C., Emmerich, B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98, 1326-1331.
41. Bertolini, F., Dell'Agnola, C., Mancuso, P., Rabascio, C., Burlini, A., Monestiroli, S., Gobbi, A., Pruneri, G., Martinelli, G. (2002) CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 62, 3106-3112.
42. Tavor, S., Petit, I., Porozov, S., Avigdor, A., Dar, A., Leider-Trejo, L., Shemtov, N., Deutsch, V., Naparstek, E., Nagler, A., Lapidot, T. (2004) CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817-2824.
43. Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai, N., Shitara, K. (2004) Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64, 2127-2133.
44. Harjunpaa, A., Junnikkala, S., Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51, 634-641.
45. Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., Introna, M. (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383-3389.
46. Harjunpaa, A., Wiklund, T., Collan, J., Janes, R., Rosenberg, J., Lee, D., Grillo-Lopez, A., Meri, S. (2001) Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk. Lymphoma 42, 731-738.
47. Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., Golay, J. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171, 1581-1587.
48. Cragg, M. S., Glennie, M. J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103, 2738-2743.
49. Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., Taylor, R. P. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172, 3280-3288.
50. Golay, J., Manganini, M., Facchinetti, V., Gramigna, R., Broady, R., Borleri, G., Rambaldi, A., Introna, M. (2003) Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88, 1002-1012.
51. Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., Reed, J. C. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99, 1038-1043.
52. Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., Jurlander, J. (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99, 1314-1319.
53. Dyall, R., Vasovic, L. V., Clynes, R. A., Nikolic-Zugic, J. (1999) Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur. J. Immunol. 29, 30-37.
54. Cragg, M. S., Morgan, S. M., Chan, H. T., Morgan, B. P., Filatov, A. V., Johnson, P. W., French, R. R., Glennie, M. J. (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045-1052.
55. Teeling, J. L., French, R. R., Cragg, M. S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P. W., Hack, C. E., Dechant, M., Valerius, T., van de Winkel, J. G., Glennie, M. J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793-1800.
56. Katrinakis, G., Kyriakou, D., Papadaki, H., Kalokyri, I., Markidou, F., Eliopoulos, G. D. (1996) Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-α. Acta Haematol. 96, 16-23.
57. Scrivener, S., Goddard, R. V., Kaminski, E. R., Prentice, A. G. (2003) Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 44, 383-389.
58. Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D., Byrd, J. C. (2004) Fc γ RIIIa and Fc γ RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103, 1472-1474.
59. Lin, T. S., Flinn, I. W., Modali, R., Lehman, T. A., Webb, J., Waymer, S., Moran, M. E., Lucas, M. S., Farag, S. S., Byrd, J. C. (2005) FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105, 289-291.
60. Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Muller, I., Wolf, E., Lipp, M. (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23-33.
61. Ghobrial, I. M., Bone, N. D., Stenson, M. J., Novak, A., Hedin, K. E., Kay, N. E., Ansell, S. M. (2004) Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin. Proc. 79, 318-325.
62. Carter, P. (2001) Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129.
63. Kipriyanov, S. M., Le Gall, F. (2004) Generation and production of engineered antibodies. Mol. Biotechnol. 26, 39-60.